Arrowhead Research | ARWR - Stock


Arrowhead Research reported $-173.08M in Stock for its fiscal quarter ending in December of 2024.





Stock Change Date
Agios Pharmaceuticals USD 35.09M 2.17M Mar/2026
Alnylam Pharmaceuticals USD 200.15M 117.43M Mar/2026
Anika Therapeutics USD 22.84M 4.05M Mar/2026
Arrowhead Research USD -173.08M 173.08M Dec/2024
Heron Therapeutics USD 54.57M 2.33M Dec/2022
Incyte USD 115.62M 14.56M Mar/2026
Ionis Pharmaceuticals USD 5.56M 4.49M Mar/2026
Ligand Pharmaceuticals USD 13.27M 4.14M Mar/2026
Merck USD 6.48B 179M Mar/2026
Moderna USD 146M 7M Mar/2026
Nektar Therapeutics USD 14.46M 1.78M Jun/2024
Novartis USD 6.29B 17M Mar/2026
Sarepta Therapeutics USD 1B 86.37M Mar/2026
TG Therapeutics USD 129.03M 3.44M Mar/2026
Ultragenyx Pharmaceutical USD 55M 3M Mar/2026
Vertex Pharmaceuticals USD 1.77B 79.9M Mar/2026